New Senior Appointment For Trakcel As It Strives To Triple Revenue By The End Of 2017

TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration, has appointed a new non-executive director as it strives to triple revenue by the end of 2017.

Anthony Davies, from Dark Horse Consulting, has been recruited to join the Board of the Wales-headquartered company to strengthen its position as the leading provider of needle-to-needle cell orchestration technology to support the development and commercialisation of regenerative therapies.

After training as a biochemist, chemical engineer and molecular biologist, Davies has worked in the cell and gene therapy field for more than 20 years.

He brings with him an extensive track record in manufacturing, operational management and commercial development.

Most recently, he was Chief Technology Officer for Capricor and Vice President of product development for Geron Corporation’s cell therapy programmes.

He received an MA in Biochemistry from the University of Cambridge and a PhD in Chemical Engineering from the University of Birmingham.

At TrakCel, Davies will use his considerable experience to provide regulatory consultancy and advice on the company’s processes and governance to contribute to the firm’s growth plans.

His regulatory expertise adds to the current leadership’s strong background in clinical research, supply chain, cell therapy development and manufacture, and information technology.

Other board members

Davies now joins the current board of directors which includes:

J. Matthew Mackowski: Chair and Managing Director, Telegraph Hill Partners;

Thomas A. Raffin: Senior partner, Telegraph Hill Partners;

Rob C. Hart: CFA Principal, Telegraph Hill Partners;

Ravi Nalliah: Chief Executive Officer, TrakCel;

Philip Roberts: Non-Exec Director.

TrakCel growth

Recently, TrakCel opened its second US office in New Jersey to achieve its growth targets, which include tripling its client base and revenue by the end of 2017.

The company also aims to increase its headcount to more than 100 in the UK and US by the end of 2019.

On his appointment, Dr. Davies, said: “TrakCel has made several significant appointments recently and I’m thrilled to join this growing and talented team at a crucial time in the firm’s development.

“I believe my background and experience in regulatory consultancy will be extremely beneficial in helping the company reach its ambitious growth targets.”

Ravi Nalliah, Chief Executive Officer at TrakCel, said: “Anthony is a great appointment for us. His strategic advice will be vital in helping us continue to streamline our processes so that we ensure our technology has maximum efficiency for the benefit of our customers.

“With a number of new appointments recently, we’re looking forward to seeing the results from our talented team.”

Ends

For media enquiries contact Jodie Phillips at Golley Slater on 02920 786099 or email jphillips@golleyslater.co.uk

About TrakCel

TrakCel's software platform provides cell and gene therapy companies with a proven solution that delivers real-time control over the entire supply chain, including manufacturing, from sample collection through to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products by improving efficiency and removing complexity while maintaining compliance and traceability from needle-to-needle.

TrakCel’s technology is increasingly being adopted by leaders in the cell and gene therapy industry. TrakCel is headquartered in Cardiff, Wales with US offices in California and New Jersey.